What unifies Huntington's, spinocerebellar ataxia and myotonic dystrophy? Ness Bermingham's new startup looks to drug that
Ness Bermingham’s latest venture brings throwbacks to some of his earliest work in biopharma. Part of his PhD work at Imperial College London revolved around triplet repeat disorders, a group of 40 or so genetic diseases characterized by the repetition and expansion of specific trinucleotide sequences. During his early years at Atlas Venture — way before he became known as a co-founder of pioneering CRISPR player Intellia — he helped create a biotech, Prestwick Pharmaceuticals, that created a Huntington’s drug dubbed tetrabenazine.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.